Author

Marla C. Dubinsky

Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)

Marla C. Dubinsky  et al.

Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)
Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)

Marla C. Dubinsky  et al.

JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)
JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)

Marla C. Dubinsky  et al.

CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS

Marla C. Dubinsky  et al.

BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky  et al.

BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS

Marla C. Dubinsky  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Marla C. Dubinsky  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky  et al.

COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marla C. Dubinsky

CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Marla C. Dubinsky  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Can we prevent IBD by targeting the intestinal microbiota?
Can we prevent IBD by targeting the intestinal microbiota?

Marla C. Dubinsky

Effectively moving forward: Shining without diminishing
Effectively moving forward: Shining without diminishing

Marla C. Dubinsky

COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marla C. Dubinsky  et al.

COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)
Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)

Marla C. Dubinsky  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Marla C. Dubinsky  et al.

Item 1 - 20 / 35
1
2